Trial Profile
A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Simufilam (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacokinetics; Proof of concept
- Sponsors Cassava Sciences
- 22 Feb 2021 According to a Cassava Sciences media release, the EOP2 meeting discussion was supported by years of scientific and clinical data, including positive results from a previously completed Phase 2 clinical program with simufilam in Alzheimers disease.
- 11 Feb 2020 Results published in the Cassava Sciences Media Release.
- 11 Feb 2020 According to an Cassava Sciences Media Release, results from this study were published in the The Journal of Prevention of Alzheimer's Disease (JPAD).